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Abstract
Purpose The purpose of this study was to evaluate how
atrial fibrillation (AF) ablation has evolved over time with
regards to patient characteristics, procedural variables, com-
plications, and outcomes.
Methods We evaluated trends over time from 2003 to 2010 in
clinical characteristics, procedural variables, complications,
and Kaplan–Meier AF-free rates after the initial and final AF
ablation in 1,125 patients undergoing 1,504 ablations.
Results Evaluating trends from 2003 to 2010, we found that
patients undergoing AF ablation became older (P<0.0001),
had higher CHADS2 scores (P<0.0001), and more coronary
artery disease (P00.021), persistent AF (P<0.0001), hyper-
tension (P<0.0001), and previous strokes/transient ischemic
attacks (P00.005). Procedure times decreased from 256±49
to 122±28 min (P<0.0005), fluoroscopy times decreased
from 134±29 to 56±19 min (P<0.0005), and major (P0
0.023), minor (P00.023), and total complications (P0
0.001) decreased over time. The learning curve to minimize
complications was 6 years. For paroxysmal AF, initial ablation
AF-free rates improved over time (P00.015) but improve-
ment plateaued in recent years. For persistent AF, initial
ablation AF-free rates trended toward improvement over time
(P00.062) but also plateaued in recent years. For long-
standing persistent AF (P00.995), there was no outcome
improvement after initial ablation over time. There was no
trend for improved final outcomes (including repeat ablations)
over time for paroxysmal, persistent, or long-standing AF (P0
0.150 to P00.978).
Conclusions Despite decreased procedural and fluoroscopy
times and reduced complication rates, post-ablation freedom
from AF has not improved commensurately in recent years.
A better understanding of AF initiation and maintenance
may be required to devise personalized approaches to AF
ablation and further improve outcomes.
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1 Introduction
The discovery of pulmonary vein (PV) tachyarrhythmias as
focal triggers of atrial fibrillation (AF) in many patients
resulted in catheter ablation as a treatment modality for AF
[1]. AF initiation and maintenance has also been attributed
in some patients to non-PV sites like the posterior left atrial
(LA) wall, ligament of Marshall, superior vena cava, coro-
nary sinus [2], vagally mediated LA ganglionated plexi (GP)
[3, 4], and areas of complex fractionated atrial electrograms
(CFAE) [5] and rotors [6]. Despite the recognized contribu-
tion of non-PV drivers to the initiation and maintenance of
AF, PV isolation remains the gold standard for ablation
aimed at eliminating symptomatic AF [7]. Studies reporting
ablation outcomes show that persistent or long-standing per-
sistent AF, LA size, and the presence of hypertension, diabetes,
coronary artery disease, and non-PV triggers decrease the
success of AF ablation [8–16]. Single procedures do not al-
ways eliminate AF and repeat ablations are an important part of
the AF ablation strategy [8]. Despite these advances, many
patients undergo AF ablation without elimination of their AF
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[17]. The present study examines a single center’s experience
with AF ablation and our changes over time in patient demo-
graphics, outcomes of initial and final ablations, procedural
variables, and complications. These temporal trends provide
insights into the evolution of AF ablation and suggest that
ablationists may need a better understanding of individual




The subjects were consecutive symptomatic patients under-
going AF ablation at Sequoia Hospital, Redwood City, CA,
USA from October 10, 2003 to December 31, 2010. All
signed written informed consent. Data collection was pro-
spective and approved by the hospital IRB. AF type was
categorized as paroxysmal (AF1: lasting <1 week), persis-
tent (AF2: lasting >1 week and <1 year or requiring phar-
macological or electrical cardioversion in <1 week), and
long-standing persistent (AF3: lasting >1 year) [7].
2.2 Ablation protocol
Our ablation protocol [8] and anticoagulation strategy
[18] have been previously published, and some of the
patients in this study were included in previous publi-
cations [8, 19]. Antiarrhythmic drugs (AADs) were
stopped ≥5 half-lives and amiodarone ≥3 months before
ablation. General anesthesia and right groin venous ac-
cess were used in most ablations. A 7 F duodecapolar
catheter (St. Jude (St. Paul, MN, USA) LivewireTM) was
placed around the tricuspid valve annulus with the distal
poles in the coronary sinus. A 9 F Boston Scientific
(Natick, MA, USA) Ultra IceTM catheter guided the trans-
septal puncture, done using a 71-cm St. Jude BRKTM or
Baylis (Montreal, QC, Canada) NRGTM needle [20]. Patients
had a femoral or radial arterial line. The St. Jude NavXTM
system was used in all cases. Prior to January 2006, we used
a closed tip catheter (Boston Scientific Blazer IITM or
Webster (Diamond Bar, CA, USA) CelsiusTM 8 mm) and,
thereafter, an open irrigated tip catheter (Webster Ther-
mocoolTM 3.5 mm or St. Jude Cool PathTM or Sapphire-
BluTM 4.0 mm). Most irrigated tip catheter ablations were
done using 50 W and the technique of “perpetual motion”
where the catheter is moved back and forth across a small area
and not left at single sites for extended times [21]. All patients
underwent circumferential atrial ablation around all PVs and a
LA roof-line ablation. Only patients with right or LA isthmus
flutter underwent a caval-tricuspid or mitral isthmus linear
ablation. Many patients had low posterior LA lines and those
with LA CFAE had them ablated. Some patients underwent
ablation in the coronary sinus (at 30–35 W) and/or superior
vena cava isolation. After wide area ablation around all veins,
a circumferential mapping catheter (7 F Webster LassoTM or
St. Jude Reflexion SpiralTM) was used to isolate all PVs
defined as complete local electrical silence indicating entrance
block. AfterMay 2010, all patients underwent pacing from the
PVs to document exit block. NavXTM activation and entrain-
ment mapping were used to ablate flutters and tachycardias.
Isoproterenol was given and non-PV triggers were mapped
and ablated.
2.3 Anticoagulation
Patients receiving warfarin continued it until 5 days pre-
procedure. Three days pre-procedure, they began enoxaparin
1 mg/kg every 12 h with the last dose 24 h pre-ablation.
Patients with AF2, AF3, or frequent AF1 underwent trans-
esophageal echocardiogram. When the transseptal sheath
entered the LA, we gave a heparin bolus followed by a
1,000-U/h infusion through the transseptal sheath adjusted by
the activated clotting time (ACT). The initial target ACT was
>300–350 s, reduced to 225 after the irrigated tip catheter was
introduced [18]. Post-ablation, we used enoxaparin 0.5 mg/kg
q12h until warfarin (continued ≥3 months) achieved an inter-
national normalized ratio (INR) of 2.0–3.0. After November
2010, some patients received dabigatran following ablation
[22].
2.4 Data collection and analysis
For each patient, we recorded age, gender, AF duration and
type, number of antiarrhythmic drugs failed, CHADS2 score,
body mass index (BMI), strokes/transient ischemic attacks
(TIAs), LA size, prior cardioversions, and comorbidities in-
cluding hypertension, diabetes, coronary artery disease, and
cardiomyopathy. For each ablation, we recorded average
ACT, fluoroscopy, and procedure time. Procedural data were
evaluated by ablation year for all initial and repeat ablations
combined. For all patients of each AF type, outcome was
determined after the initial ablation by year of procedure and
after the final ablation by year of procedure. Due to the small
number of patients, years 2003 and 2004 were combined.
2.5 Complications
Complications were categorized as major or minor by the
year of ablation for the combined initial and repeat ablations.
Major complications included death, pericardial tamponade,
stroke, atrio-esophageal fistula, PV stenosis >50% requiring
intervention, groin complications requiring surgery or transfu-
sion, heart block, severe tongue hematoma due to intubation,
and severe protamine reaction. Minor complications included
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transient cough, elective late pericardiocentesis, groin compli-
cations treated with a minor procedure, esophageal irritation
requiring no intervention, PV stenosis >50% not requiring
intervention, pacer lead dislodgement, TIA, urethral trauma,
urinary tract infection, mild tongue hematoma due to intuba-
tion, and pneumonia.
2.6 Follow-up
Many patients were treated with AADs during the 3-
month blanking period post-ablation. Patients transmitted
daily electrocardiogram (ECG) strips for 1–3 months
post-ablation and were seen at 3 months when an echo-
cardiogram and ambulatory ECG monitor for ≥24 h were
performed. Initial ablation failures, defined as recurrent
AF, tachycardia, or flutter lasting >30 s off of drugs
≥3 months post-procedure, were encouraged to undergo
a repeat ablation. Patients were seen or contacted fre-
quently from 3–12 months and came for a 1-year follow-
up with echocardiogram and 24-h ECG. Thereafter,
every 6–12 months, patients were seen directly or
contacted via telephone by research nurses or the attending
physician, and arrhythmia records were obtained from hospi-
tals and referring physicians. Patients were advised to call for
arrhythmia symptoms and ECG recorders were reissued to
them. During 2011, all patients considered AF-free >1 year
post final ablation were encouraged to undergo a 1-week
continuous monitor. Late pacemaker AF data were utilized
when available. One patient was lost to follow-up.
2.7 Statistical analysis
Statistical analysis was done using XLSTAT 2010 (Paris,
France). Continuous data were described as mean ± standard
deviation and categorical data as counts and percentages.
Analysis of variance and the Cochran–Armitage trend anal-
ysis were used to compare procedural variables including
average ACT, procedure and fluoroscopy times, and com-
plications, as well as clinical parameters including age,
gender, BMI, AF duration and type, number of AADs
failed, prior cardioversions, LA size, CHADS2 score, and
the presence of coronary artery disease, dilated cardiomy-
opathy, hypertension, and prior stoke/TIA among patients
grouped by year of initial ablation. Kaplan–Meier curves
were generated for AF-free survival by AF type and by
ablation year for the initial ablation and for final outcome
by the year of the last ablation. All tests were two-sided and
P<0.05 was considered statistically significant.
3 Results
3.1 Patient population
The subjects were 1,125 consecutive patients who underwent
1,504 ablations for symptomatic AF. Table 1 shows the patient
characteristics by year of initial ablation. The number of initial
ablations increased from 40 to 280 from 2003 to 2010. The
total number of ablations/year increased from 43 to 380. There
Table 1 Clinical characteristics by year of initial ablation
2003–2004 2005 2006 2007 2008 2009 2010 P value
Initial ablations 40 65 133 170 196 241 280 NA
Repeat ablations 3 (7.0%) 14 (17.7%) 43 (24.4%) 63 (27.0%) 71 (26.6%) 85 (26.1%) 100 (26.3%) 00.036*
Total ablations 42 79 176 233 267 326 380 NA
Age (years) 59.0±11.1 58.4±10.5 61.6±9.9 61.4±10.6 62.1±10.3 62.8±10.0 64.3±10.0 <0.0001*
Gender (% female) 35.0% 23.1% 23.3% 30.6% 25.5% 30.3% 31.8% 00.202
Duration of AF (years) 5.6±5.3 7.9±8.0 6.9±6.8 6.6±7.8 5.9±6.2 6.7±7.8 6.0±6.5 00.336
# Drugs failed 1.55±0.96 1.58±1.01 1.41±1.18 1.22±1.00 1.15±0.97 1.25±0.98 1.34±1.14 00.336
Average CHADS2 score 0.77±0.95 0.58±0.88 0.78±0.83 0.70±0.88 0.78±0.97 0.91±0.94 1.15±1.08 <0.0001*
Body mass index 28.1±4.3 29.2±5.5 29.5±5.4 29.5±5.4 29.3±5.1 29.5±5.4 29.9±5.6 00.601
LA size (cm) 4.13±0.77 4.36±0.66 4.37±0.62 4.38±0.67 4.31±0.71 4.26±0.67 4.29±0.72 00.308
Hypertension 45.0% 24.6% 40.6% 38.8% 46.4% 49.0% 57.9% <0.0001*
Diabetes 10.0% 13.8% 6.8% 7.1% 8.2% 5.8% 12.9% 00.458
Cardiomyopathy 2.5% 13.3% 10.5% 9.4% 5.1% 7.1% 8.9% 00.710
Coronary artery disease 7.5% 10.8% 8.3% 11.8% 15.3% 15.5% 15.0% 00.021*
Prior cardioversion 45.0% 44.6% 44.4% 47.6% 46.4% 46.3% 48.6% 00.415
Prior stroke/TIA 2.5% 1.5% 8.3% 3.5% 6.1% 7.1% 8.9% 00.005*
AF atrial fibrillation, TIA transient ischemic attack, NA not applicable
*P<0.05
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was a gradual increase in age from 59.0±11.1 to 64.3±
10.0 years (P<0.0001) and an increase in the average
CHADS2 score from 0.77±0.95 to 1.15±1.08 (P<0.0001).
Over time, more patients had comorbidities including hyper-
tension (P<0.0001), coronary artery disease (P<0.021) and
prior strokes/TIAs (P00.005). Although there were more
repeat ablations (P00.036) over time, this largely resulted
from the fact that in the early years of our AF ablation
program, there were only initial ablations. From approximate-
ly 2007 to 2010, the percentage of repeat ablations remained
stable at 26%. There was no change in gender, number of
AADs failed, duration of AF prior to ablation, BMI, or LA
size over time.
There was a gradual change in the composition of
patients referred for AF ablation by AF type (Fig. 1). There
was a slight decrease in the number of patients with AF1
which did not reach statistical significance (P00.07), a
decline in the number with AF3 (P<0.001) and an increase
in the number with AF2 (P<0.0001).
3.2 Procedural variables
Figure 2 shows the average procedural and fluoroscopy times
for the combination of initial and repeat ablations by year.
From 2003–2004 to 2010, there was a significant shortening
of procedure times from 256±49 to 122±28 min (P<0.0005)
and fluoroscopy times from 134±29 to 56±9 min (P<
0.0005). Figure 3 shows the decrease in ACT (from 338±30
to 229±21 s, P<0.0001) over time.
3.3 Outcomes by year
Figure 4 shows the Kaplan–Meier curves for freedom from
AF after initial ablation by year and AF type. Figure 4(A)
shows a statistically significant year-to-year improvement in
outcomes after the initial ablation for AF1 patients (P0
0.015). Despite the overall improvement, inspection of the
Kaplan–Meier curves shows little improvement after 2006.
Figure 4(B) shows a trend towards year-to-year improvement
in initial ablation outcomes for AF2 patients (P00.062) with
no improvement after 2007. Figure 4(C) shows year-to-year
initial ablation outcomes for AF3 patients and demonstrates
no improvement over the years (P00.995).
Figure 5 shows the Kaplan–Meier curves for the outcome
after the final ablation (average of 1.34 ablations/patient) by
year of last ablation. Figure 5(A–C) shows that there was no
improvement over time for the final outcome in patients with
AF1 (P00.325), AF2 (P00.150), or AF3 (P00.978). For both
AF1 and AF2, the rates of freedom from AF after the final
ablation for 2010 may be artificially low due to the fact that
many of these patients have only undergone an initial ablation.
3.4 Procedural complications
Figure 6 shows the trend over time for procedural complica-
tions for the combination of initial and repeat ablations by year.
Major procedural complications have decreased gradually
from 4.65% of ablations in 2003–2004 to 0.53% in 2010
Fig. 1 Percentage of AF patients with each type of AF (green 0
paroxysmal AF1, blue 0 persistent AF2, and black 0 long-standing
persistent AF3) by year of initial ablation
Fig. 2 Changes in procedure and fluoroscopy time (green 0 procedure
time, blue 0 fluoroscopy time) by year of initial ablation
Fig. 3 Decline in average procedural ACT by year
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(P00.023). Minor complications also decreased over time
from 4.65% in 2003 and 2004 to 1.05% in 2010 (P00.023).
The combined total of major and minor complications de-
creased from 9.30% to 1.58% over time (P00.001). The shape
of the curve indicates a long learning curve of about 6 years to
minimize ablation complications. All individual major and
minor complications over time are shown in Table 2. There
were no deaths, atrio-esophageal fistulae, or PV stenoses re-
quiring intervention. Although the total number of complica-
tions decreased over time, the incidence of pericardial
tamponade was the only individual complication to decrease
over time (P00.02).
4 Discussion
This study reveals two key trends that occurred over time at
our institution: (1) the clinical characteristics of patients
undergoing AF ablation changed and (2) post-procedure
outcomes did not improve commensurate with improve-
ments in procedural performance. From 2003 to 2010, there
was a gradual change in the baseline demographics of
patients undergoing AF ablation. Patients are now older
with higher CHADS2 scores and more persistent AF. The
recognition of these trends is critical because of the key role
that clinical factors play in determining AF ablation effica-
cy. The fact that LA size, duration of AF, number of AADs
failed and prior cardioversions did not change over time
suggests that patients are not being referred for ablation
earlier in their disease process. The outcomes of AF ablation
might be improved by earlier referral.
Despite optimization of procedural factors, i.e., performing
AF ablations faster and with fewer complications, our out-
comes after the initial and final ablation have either not
improved or have plateaued. Improvements in outcomes for
initial ablations over time were greatest for AF1 and least for
AF3. However, even for AF1, ablation outcomes seem to have
reached a ceiling several years ago. Although we appear to
have optimized our AF-free rates after a few years of ablation
experience, it took approximately 6 years and almost 800
ablations for the complication rates to reach a nadir. This
suggests that the learning curve for performing ablations
safely is not insignificant even in the hands of experienced
ablationists. Part of our reduction in complications may be due
to operator experience; however, part is due to procedural
changes such as using only one groin for all venous access
and the use of the radiofrequency transseptal needle which we
Fig. 4 Kaplan–Meier curves for freedom from AF after initial AF ablation by year ((A) paroxysmal AF1, (B) persistent AF2, (C) long-standing
persistent AF3). Blue 0 2003–2004, purple 0 2005, red 0 2006, green 0 2007, black 0 2008, gray 0 2009, yellow 0 2010
Fig. 5 Kaplan–Meier curves for freedom from AF after the last AF ablation by year of last ablation. (A) Paroxysmal AF1, (B) persistent AF2, (C)
long-standing persistent AF3. Color code the same as Fig. 4
J Interv Card Electrophysiol (2012) 34:115–123 119
have shown to reduce the incidence of pericardial tamponade
[20]. While we recognize that most centers keep their target
ACT >300–350 s, we have found that lowering our target
ACT level reduced our overall vascular and hemorrhagic
complication rate [18]. It is important to emphasize that when
keeping the target ACT lower, one must use only a single
transseptal puncture and should infuse maintenance heparin
through the transseptal sheath. The change to general anes-
thesia [23] and the use of the irrigated tip ablation catheter at
50 W [21] early in our ablation series may also have contrib-
uted to procedural improvements over time.Many centers now
perform AF ablation on patients with a therapeutic INR.
However, it is becoming more difficult to do uninterrupted
oral anticoagulation as more patients are referred for ablation
on the direct thrombin inhibitor, dabigitran, which has no
reversal agent, making it potentially dangerous to perform a
procedure on a fully orally anticoagulated patient [22].
Lemola et al. [24] showed that when an initial ablation
has failed, repeat electroanatomic mapping shows that
≥1 PVs have reconnected in 98% of patients. PV reconnec-
tion is not necessarily, however, the only cause of ablation
failure. It is also possible that even if we can permanently
eliminate all existing PV–LA connections with a single pro-
cedure, new connections may regenerate de novo over time.
Studies have shown that PV isolation is not necessarily needed
to eliminate AF [25]; for example, ablation of CFAEs or left
atrial GP can eliminate AF in some patients [3–5]. In a
randomized trial of AF1 patients, Katritsis et al. [3] reported
that 45.5% were AF-free with PV isolation alone compared
with 73.5% with PV isolation plus GP ablation at 4.7 months
post-ablation. In our series, the wide area circles we ablate
around all veins prior to using a circular catheter to finish vein
isolation encompass the major anatomical locations of
GP, probably accomplishing both PV isolation and GP
ablation. Our AF-free rate after a single ablation is virtu-
ally identical to those of Katritsis et al. [3] in patients who
received both PV isolation and GP ablation. The role of rotors
and CFAEs in AF ablation remains incompletely understood.
Preliminary evidence suggests that ablating rotors may also
alleviate AF [6].
Fig. 6 Percent of AF ablations with major (red) and minor (blue)
complications by year. The black line represents the total complications
(major + minor) by year
Table 2 Complications by year of initial ablation
2003–2004 2005 2006 2007 2008 2009 2010 P value
Total ablations 43 79 176 233 267 326 380 NA
Cough which resolved 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.7%) 0 (0.0%) 1 (0.3%) 00.22
Groin complications (major + minor) 0 (0.0%) 1 (1.3%) 4 (2.3%) 1 (0.4%) 6 (2.2%) 1 (0.3%) 1 (0.3%) 00.11
Esophageal irritation 0 (0.0%) 0 (0.0%) 1 (0.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 00.22
PV stenosis >50% no intervention 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 00.97
Pacer lead dislodgment 0 (0.0%) 0 (0.0%) 1 (0.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 00.22
Urethral trauma 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 00.52
Severe urinary infection 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 00.07
Pneumonia 1 (2.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 00.19
Eye keratopathy, transient 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 00.25
Tongue hematoma (major + minor) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 00.10
Elective, non-tamponade pericaridocentesis 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.07
Pericardial tamponade 1 (2.3%) 1 (1.3%) 1 (0.6%) 3 (1.3%) 2 (0.7%) 1 (0.3%) 0 (0.0%) 00.02a
Stroke/TIA 2 (4.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.3%) 1 (0.3%) 00.15
Severe protamine reaction 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 00.97
Heart block 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 00.52
Total 4 (9.3%) 4 (5.1%) 7 (4.0%) 7 (3.0%) 13 (4.9%) 4 (1.2%) 6 (1.6%) 00.001a
TIA transient ischemic attack, NA not applicable
a Statistically significant
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Our data also suggest that one cannot use long-term out-
comes from patients with paroxysmal AF ablations years
ago to judge the efficacy of contemporary ablations.
Weerasooriya et al. [26] reported only a 40% long-
term success rate after a single procedure done in Bor-
deaux, France in 2001–2002. A more contemporary series
from that center reported a 1-year AF-free rate of 61.8%
after a single procedure [27].
Many of the new AF ablation technologies may not be
able to significantly improve AF ablation results. Robotic
[28] and magnetic navigation systems [27] do the job that
ablationists do manually with a different technology but do
not contribute to a better understanding of what we should
be ablating. Although it is theoretically possible that better
tissue contact with a robotic system could result in better
ablation outcomes, early results do not suggest this is the
case. In a study randomizing patients to manual catheter
manipulation vs. magnetically controlled ablation, there
was no difference in outcome and patient radiation exposure
and procedure time increased with the magnetic navigation
system [27]. Other technologies holding promise for improved
PV isolation have not yet demonstrated improved outcomes.
The cryoballoon is another promising new technology for AF
ablation. A recent literature review of the efficacy of this
technology showed a single procedure 1-year AF-free rate of
69.9% to 76.7% for paroxysmal AF and 41.9% to 48.4% for
persistent AF [29]. These numbers do not suggest that the
cryoballoon will dramatically increase the success of AF abla-
tion. In this era of economic constraints, new technologies
must be evaluated carefully for contributions to impoved safety
and/or efficacy of AF ablation as virtually all increase proce-
dural costs.
AF ablation improves the quality of life in a high per-
centage of patients undergoing the procedure. Although AF
ablation currently has a high rate of success [9–16], it would
be desirable to eliminate AF in an even greater number of
patients and to decrease the need for repeat ablations [8]. In
order to incrementally improve ablation outcomes, we need
a better understanding of AF. The diversity of potential AF
mechanisms and our lack of understanding of how AF
occurs in individual patients are summarized in an editorial
by Katritsis and Camm [30]. We need new and improved
methods to identify the exact AF triggers and perpetuators in
each patient. For example, it might be useful to have am-
bulatory body surface mapping to document the site of
origin of AF in ambulatory patients prior to ablation.This
might allow us to target a particular PV or a non-PV trigger
causing AF in an individual patient with less widespread
ablation. We might also discover that individual patients
have multiple initiators and that the mechanism of AF can
change over time. It is likely that the best immediately
available technique for improving ablation outcome is for
patients to have ablation earlier in the disease process before
they develop LA dilatation, fail numerous AADs [31], and
progress from AF1 to AF2 or AF3.
4.1 Limitations
Our data are from a single referral center case series which has
inherent limitations including patient selection and referral
bias. It is difficult to determine how much of our temporal
reduction in complications was due to improved operator skill
vs. procedural modifications over time, such as lowering our
target ACT [18] or utilizing the RF transseptal needle [20]. As
in all long-term follow-up studies, the ability to monitor
patients decreased over time and we could havemissed asymp-
tomatic AF despite our regular follow-up and frequent contact
by trained research personnel. Despite its shortcomings, our
method of long-term follow-up is essentially the same as that
used by most other referral centers reporting on long-term
outcomes of AF ablations [11, 12, 26, 32]. Any missed asymp-
tomatic AF should have occurred equally across all years and
is not likely to have changed the conclusions of our study.
5 Conclusions
The AF ablation procedure has progressed over the last decade
and, based on our experience, can be done increasingly faster
and more safely, with shorter fluoroscopy and procedure times
than at its inception. Despite these procedural advances, AF
ablation appears to have plateaued with regard to our ability to
eliminate AF in a higher percentage of patients. New technol-
ogies such as robotic and magnetic navigation systems and
cryoballoon ablation systems do not seem to dramatically
improve current ablation outcomes, as they only allow us to
do what we are already doing with a different tool, rather than
help us decide what we should be ablating in each individual
patient. Breaking through the ceiling on AF ablation efficacy
that we reached several years ago will probably require im-
proved understanding of the mechanism of AF initiation and
maintenance in individual patients in order to personalize
ablation protocols to each patient’s needs. The precise pathway
to this new paradigm is a bit unclear but perhaps new technol-
ogy that reveals the mechanisms of AF rather than technology
designed to ablate AF might lead us there more rapidly.
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